Dr. Reddy's Laboratories Receives FDA Tentative Approval for Generic Version of Gilead's Yeztugo
Dr. Reddy's Laboratories (RDY) has secured tentative U.S. FDA approval for its generic version of Yeztugo, making it the first manufacturer to achieve this milestone. The drug is a twice-yearly preventative medicine used in HIV prevention. The approval marks a significant competitive shift in the HIV preventative market, directly challenging Gilead Sciences (GILD), the original developer of Yeztugo. This development signals increased competition for long-acting HIV prevention therapies in the United States.
Topics: FDA approval generic drugs HIV prevention
Read the full article at Seeking Alpha
Part of the story Dr. Reddy's granted FDA nod for first generic targeting Gilead’s Yeztugo (2 articles)